ArticleStem cell research & therapy2017
In vitro generation of Sertoli-like and haploid spermatid-like cells from human umbilical cord perivascular cells.
Article in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Mesenchymal Stem Cells (MSCs) Therapy for Recovery of Fertility: a Systematic Review.Stem cell reviews and reports · 2018Pooled it
- Effect of Adding Human Umbilical Cord Mesenchymal Stem Cells-Derived Secretome on Sperm Quality Improvement by Swim-Up Method.Obstetrics and gynecology international · 2026Article
- Low-level lasers can improve spermatogenesis in infertile mice by targeting molecular pathways.BioImpacts : BI · 2026Article
- In Vitro Gamete Production in Mammals: Decades of Pioneering Approaches in Germ Cell and Stem Cell Biology Supporting Innovative Discovery and Expansion of Human Reproductive Potential.Molecular reproduction and development · 2025Review
- In vivo and in vitro sperm production: an overview of the challenges and advances in male fertility restoration.Clinical and experimental reproductive medicine · 2024Article
- Reprograming skin fibroblasts into Sertoli cells: a patient-specific tool to understand effects of genetic variants on gonadal development.Biology of sex differences · 2024Article
- Multipotent fetal stem cells in reproductive biology research.Stem cell research & therapy · 2023Review
- Effects of clinical medications on male fertility and prospects for stem cell therapy.Frontiers in cell and developmental biology · 2023Review
- Current status and reflections on fertility preservation in China.Journal of assisted reproduction and genetics · 2022Review
- Review
- Review
- An In Vitro Differentiation Protocol for Human Embryonic Bipotential Gonad and Testis Cell Development.Stem cell reports · 2020Article
- Stem cell-based therapies for fertility preservation in males: Current status and future prospects.World journal of stem cells · 2020Review
- Article
- Pluripotent Cell Models for Gonadal Research.International journal of molecular sciences · 2019Review
- Differential Proliferation Effects after Short-Term Cultivation of Mouse Spermatogonial Stem Cells on Different Feeder Layers.Cell journal · 2019Article
- Spermatogonial stem cell transplantation and male infertility: Current status and future directions.Arab journal of urology · 2018Review
- Male germline stem cells in non-human primates.Primate biology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFirst trimester (FTM) and term human umbilical cord-derived perivascular cells (HUCPVCs), which are rich sources of mesenchymal stem cells (MSCs), can give rise to Sertoli cell (SC)-like as well as haploid germ cell (GC)-like cells in vitro using culture conditions that recapitulate the testicular niche. Gamete-like cells have been produced ex vivo using pluripotent stem cells as well as MSCs. However, the production of functional gametes from human stem cells has yet to be achieved.
methodsThree independent lines of FTM and term HUCPVCs were cultured using a novel 5-week step-wise in vitro differentiation protocol recapitulating key physiological signals involved in testicular development. SC- and GC-associated phenotypical properties were assessed by real-time polymerase chain reaction (RT-PCR), quantitative PCR immunocytochemistry, flow cytometry, and fluorescence in-situ hybridization (FISH). Functional spermatogonial stem cell-like properties were assessed using a xenotranplantation assay.
resultsWithin 3 weeks of differentiation, two morphologically distinct cell types emerged including large adherent cells and semi-attached round cells. Both early GC-associated markers (VASA, DAZL, GPR125, GFR1α) and SC-associated markers (FSHR, SOX9, AMH) were upregulated, and 5.7 ± 1.2% of these cells engrafted near the inner basal membrane in a xenograft assay. After 5 weeks in culture, 10-30% of the cells were haploid, had adopted a spermatid-like morphology, and expressed PRM1, Acrosin, and ODF2. Undifferentiated HUCPVCs secreted key factors known to regulate spermatogenesis (LIF, GDNF, BMP4, bFGF) and 10-20% of HUCPVCs co-expressed SSEA4, CD9, CD90, and CD49f. We hypothesize that the paracrine properties and cellular heterogeneity of HUCPVCs may explain their dual capacity to differentiate to both SC- and GC-like cells.
conclusionsHUCPVCs recapitulate elements of the testicular niche including their ability to differentiate into cells with Sertoli-like and haploid spermatid-like properties in vitro. Our study supports the importance of generating a niche-like environment under ex vivo conditions aiming at creating mature GC, and highlights the plasticity of HUCPVCs. This could have future applications for the treatment of some cases of male infertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.